Compare · DXCM vs XRAY
DXCM vs XRAY
Side-by-side comparison of DexCom Inc. (DXCM) and DENTSPLY SIRONA Inc. (XRAY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and XRAY operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $26.65B, about 13.1x XRAY ($2.03B).
- XRAY has been more active in the news (23 items in the past 4 weeks vs 18 for DXCM).
- Both have 25 recent analyst ratings on file.
- Company
- DexCom Inc.
- DENTSPLY SIRONA Inc.
- Price
- $69.39+0.48%
- $10.18+0.25%
- Market cap
- $26.65B
- $2.03B
- 1M return
- -3.41%
- -
- 1Y return
- -13.05%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 1987
- News (4w)
- 18
- 23
- Recent ratings
- 25
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
DENTSPLY SIRONA Inc.
DENTSPLY SIRONA Inc. designs, develops, manufactures, distributes, and sells various dental products and technologies primarily for professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression and restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers. The company also offers dental laboratory products, such as dental prosthetics that include artificial teeth, precious metal dental alloys, dental ceramics, and crown and bridge materials; and laboratory-based CAD/CAM milling systems, amalgamators, mixing machines, and porcelain furnaces. In addition, it provides dental technology products, including dental implants and related scanning equipment, and treatment software; orthodontic clear aligners and appliances for dental practitioners and specialist; and dental equipment, such as treatment centers, imaging equipment, dental handpieces, and computer aided design and machining systems for dental practitioners. Further, the company offers healthcare consumable products, such as urology catheters, medical drills, and other non-medical products. It markets and sells dental products through distributors, dealers, and importers; dental hygienists, assistants, laboratories, and schools; and urology products directly to patients, as well as through distributors to urologists, continence care nurses, general practitioners, and direct-to-patients. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1899 and is headquartered in Charlotte, North Carolina.
Latest DXCM
- Dexcom Further Advances Vision of Glucose Biosensing for All
- Deutsche Bank initiated coverage on Dexcom with a new price target
- EVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)
- Director Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
Latest XRAY
- Amendment: Director Mazelsky Jonathan Jay bought $101,400 worth of shares (10,000 units at $10.14), increasing direct ownership by 19% to 61,669 units (SEC Form 4)
- New insider Barton-Brobst Lindi Rene claimed ownership of 45,440 shares (SEC Form 3)
- Director Hosein Clyde bought $64,902 worth of shares (6,500 units at $9.98), increasing direct ownership by 10% to 70,575 units (SEC Form 4)
- Director Mckeon Brian P bought $101,200 worth of shares (10,000 units at $10.12) (SEC Form 4)
- Director Gladden Brian T bought $100,000 worth of shares (9,985 units at $10.02), increasing direct ownership by 19% to 61,849 units (SEC Form 4)
- Director Mazelsky Jonathan Jay was granted 10,000 shares, increasing direct ownership by 19% to 61,669 units (SEC Form 4)
- Director Holden Betsy D bought $99,692 worth of shares (10,086 units at $9.88), increasing direct ownership by 13% to 87,528 units (SEC Form 4)
- Director Barber Michael J bought $150,005 worth of shares (15,175 units at $9.88), increasing direct ownership by 37% to 55,943 units (SEC Form 4)
- DENTSPLY SIRONA Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dentsply Sirona Appoints John Fortson as Chief Financial Officer